KayoThera, founded with a mission to revolutionize cancer treatment, is a biotechnology company focused on developing first-in-class therapeutics for advanced and metastatic cancers. The company's vision is to transform the retinoid pathway, previously deemed "undruggable," into a viable target for cancer therapy. KayoThera specializes in creating novel, safe oral antagonists that inhibit retinoid signaling, offering new hope for patients with late-stage cancers.

Notable figures affiliated with KayoThera include leading scientists and industry veterans who bring extensive experience in oncology and drug development. The company has attracted significant interest and investment from prominent biotech investors, underscoring its potential impact. KayoThera's key achievements include advancing the understanding of the retinoid pathway and developing groundbreaking oral inhibitors that could significantly improve cancer treatment outcomes.